Central Nervous System (CNS) Therapeutic Market By Software Disease - Global Industry Analysis & Forecast to 2027

Published On : October 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC101425

SEGMENTS & REGIONS:

  • Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa

Central Nervous System (CNS) Therapeutic Market By Disease (Trauma, Degenerative, Cancer, Neurovascular Disease, Mental Health and Infections) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Central Nervous System (CNS) Therapeutic Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.  Development in therapeutics, diagnostics, and drug discovery procedures are principally driving the development of the market. In addition, rising interest for powerful restorative choices are propelling real pharmaceutical organizations to contribute on R&D for the equivalent, consequently making development opportunities for the market. Moreover, developing aged populace inclined to different CNS infections including Alzheimer's and schizophrenia is anticipated to fuel the development. Besides, the quantity of patients is anticipated to develop with expanding commonness of CNS issues related with stationary way of life and constant mental health problems.

Market Segmentation

Based on disease mental health section ruled the market in 2017 and is anticipated to proceed with its predominance all through the estimate time frame. Expanding number of patients with mental health problems, broad R&D, increasing number of rehabilitation settings, and the advent of novel treatment systems are prime elements driving development.

Regional Insights

North America ruled the market by accounting for the biggest share in 2017. This can be credited to aspects such as increasing number of reported cases of anxiety & depression and rising implementation of advanced therapeutics.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Pfizer, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Merck & Co.
  • Shire PLC
  • Teva Pharmaceuticals
  • Biogen, Inc.
  • Eli Lily
  • Astra Zeneca
  • Novartis AG
  • Johnson & Johnson

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Central Nervous System (CNS) Therapeutic Market, By Disease, Estimates and Forecast, 2017-2027 ($Million)

·         Trauma

·         Degenerative

·         Cancer

·         Neurovascular Disease

·         Mental Health

·         Infections

·         Central Nervous System (CNS) Therapeutic Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

·         North America

§  North America Central Nervous System (CNS) Therapeutic Market, By Country

o    U.S. Central Nervous System (CNS) Therapeutic Market

o    Canada Central Nervous System (CNS) Therapeutic Market

o    Mexico Central Nervous System (CNS) Therapeutic Market

·         Europe

§  Europe Central Nervous System (CNS) Therapeutic Market, By Country

o    Germany Central Nervous System (CNS) Therapeutic Market

o    UK Central Nervous System (CNS) Therapeutic Market

o    France Central Nervous System (CNS) Therapeutic Market

o    Russia Central Nervous System (CNS) Therapeutic Market

o    Italy Central Nervous System (CNS) Therapeutic Market

o    Rest of Europe Central Nervous System (CNS) Therapeutic Market

·         Asia-Pacific

§  Asia-Pacific Central Nervous System (CNS) Therapeutic Market, By Country

o    China Central Nervous System (CNS) Therapeutic Market

o    Japan Central Nervous System (CNS) Therapeutic Market

o    South Korea Central Nervous System (CNS) Therapeutic Market

o    India Central Nervous System (CNS) Therapeutic Market

o    Southeast Asia Central Nervous System (CNS) Therapeutic Market

o    Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Market

·         South America

§  South America Central Nervous System (CNS) Therapeutic Market

o    Brazil Central Nervous System (CNS) Therapeutic Market

o    Argentina Central Nervous System (CNS) Therapeutic Market

o    Columbia Central Nervous System (CNS) Therapeutic Market

o    Rest of South America Central Nervous System (CNS) Therapeutic Market

·         Middle East and Africa

§  Middle East and Africa Central Nervous System (CNS) Therapeutic Market

o    Saudi Arabia Central Nervous System (CNS) Therapeutic Market

o    UAE Central Nervous System (CNS) Therapeutic Market

o    Egypt Central Nervous System (CNS) Therapeutic Market

o    Nigeria Central Nervous System (CNS) Therapeutic Market

o    South Africa Central Nervous System (CNS) Therapeutic Market

o    Rest of MEA Central Nervous System (CNS) Therapeutic Market

Table of Contents

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Central Nervous System (CNS) Therapeutic Market, By Disease

5.1.     Introduction

5.2.     Global Central Nervous System (CNS) Therapeutic Revenue and Market Share by Disease (2017-2027)

5.2.1.  Global Central Nervous System (CNS) Therapeutic Revenue and Revenue Share by Disease (2017-2027)

5.3.     Trauma

5.3.1.  Global Trauma Revenue and Growth Rate (2017-2027)

5.4.     Degenerative

5.4.1.  Global Degenerative Revenue and Growth Rate (2017-2027)

5.5.     Cancer

5.5.1.  Global Cancer Revenue and Growth Rate (2017-2027)

5.6.     Neurovascular Disease

5.6.1.  Global Neurovascular Disease Revenue and Growth Rate (2017-2027)

5.7.     Mental Health

5.7.1.  Global Mental Health Revenue and Growth Rate (2017-2027)

5.8.     Infections

5.8.1.  Global Infections Revenue and Growth Rate (2017-2027)

6.       Central Nervous System (CNS) Therapeutic Market, By Region

6.1.     Introduction

6.2.     Global Central Nervous System (CNS) Therapeutic Revenue and Market Share by Regions

6.2.1.  Global Central Nervous System (CNS) Therapeutic Revenue by Regions (2017-2027)

6.3.     North America Central Nervous System (CNS) Therapeutic by Countries

6.3.1.  North America Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2027)

6.3.2.  North America Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2027)

6.3.3.  United States

6.3.3.1.  United States Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.4.  Canada

6.3.4.1.  Canada Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.5.  Mexico

6.3.5.1.  Mexico Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.     Europe Central Nervous System (CNS) Therapeutic by Countries

6.4.1.  Europe Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2027)

6.4.2.  Europe Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2027)

6.4.3.  Germany

6.4.3.1.  Germany Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.4.  France

6.4.4.1.  France Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.5.  UK

6.4.5.1.  UK Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.6.  Russia

6.4.6.1.  Russia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.7.  Italy

6.4.7.1.  Italy Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.8.  Rest of Europe

6.4.8.1.  Rest of Europe Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.     Asia-Pacific Central Nervous System (CNS) Therapeutic by Countries

6.5.1.  Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2027)

6.5.2.  Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2027)

6.5.3.  China

6.5.3.1.  China Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.4.  Japan

6.5.4.1.  Japan Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.5.  Korea

6.5.5.1.  Korea Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.6.  India

6.5.6.1.  India Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.7.  Southeast Asia

6.5.7.1.  Southeast Asia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.8.  Rest of Asia-Pacific

6.5.8.1.  Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.     South America Central Nervous System (CNS) Therapeutic by Countries

6.6.1.  South America Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2027)

6.6.2.  South America Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2027)

6.6.3.  Brazil

6.6.3.1.  Brazil Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.4.  Argentina

6.6.4.1.  Argentina Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.5.  Columbia

6.6.5.1.  Columbia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.6.  Rest of South America

6.6.6.1.  Rest of South America Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.     Middle East and Africa Central Nervous System (CNS) Therapeutic by Countries

6.7.1.  Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2027)

6.7.2.  Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2027)

6.7.3.  Saudi Arabia

6.7.3.1.  Saudi Arabia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.4.  United Arab Emirates

6.7.4.1.  United Arab Emirates Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.5.  Egypt

6.7.5.1.  Egypt Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.6.  Nigeria

6.7.6.1.  Nigeria Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.7.  South Africa

6.7.7.1.  South Africa Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.8.  Turkey

6.7.8.1.  Turkey Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.  Rest of Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

7.       Company Profiles

7.1.     Pfizer, Inc.

7.1.1.  Business Overview

7.1.2.   Service Portfolio

7.1.3.  Strategic Developments

7.1.4.   Revenue and Market Share

7.2.     Otsuka Pharmaceutical Co., Ltd.

7.2.1.  Business Overview

7.2.2.   Service Portfolio

7.2.3.  Strategic Developments

7.2.4.   Revenue and Market Share

7.3.     Merck & Co.

7.3.1.  Business Overview

7.3.2.   Service Portfolio

7.3.3.  Strategic Developments

7.3.4.   Revenue and Market Share

7.4.     Shire PLC

7.4.1.  Business Overview

7.4.2.   Service Portfolio

7.4.3.  Strategic Developments

7.4.4.   Revenue and Market Share

7.5.     Teva Pharmaceuticals

7.5.1.  Business Overview

7.5.2.   Service Portfolio

7.5.3.  Strategic Developments

7.5.4.   Revenue and Market Share

7.6.     Biogen, Inc.

7.6.1.  Business Overview

7.6.2.   Service Portfolio

7.6.3.  Strategic Developments

7.6.4.   Revenue and Market Share

7.7.     Eli Lily

7.7.1.  Business Overview

7.7.2.   Service Portfolio

7.7.3.  Strategic Developments

7.7.4.   Revenue and Market Share

7.8.     Astra Zeneca

7.8.1.  Business Overview

7.8.2.   Service Portfolio

7.8.3.  Strategic Developments

7.8.4.   Revenue and Market Share

7.9.     Novartis AG

7.9.1.  Business Overview

7.9.2.   Service Portfolio

7.9.3.  Strategic Developments

7.9.4.   Revenue and Market Share

7.10. Johnson & Johnson

7.10.1.      Business Overview

7.10.2.       Service Portfolio

7.10.3.      Strategic Developments

7.10.4.       Revenue and Market Share

8.       Global Central Nervous System (CNS) Therapeutic Market Competition, by Manufacturer

8.1.     Global Central Nervous System (CNS) Therapeutic Revenue and Market Share by Manufacturer (2017-2017)

8.2.     Global Central Nervous System (CNS) Therapeutic Price By Region (2017-2017)

8.3.     Top 5 Central Nervous System (CNS) Therapeutic Manufacturer Market Share

8.4.     Market Competition Trend

9.       Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.1.     Global Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2027)

9.2.     Central Nervous System (CNS) Therapeutic Market Forecast by Regions (2017-2027)

9.2.1.  North America Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.1.1.  United States Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.1.2.  Canada Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.1.3.  Mexico Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.  Europe Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.1.  Germany Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.2.  France Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.3.  UK Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.4.  Russia Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.5.  Italy Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.2.6.  Rest of Europe Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.  Asia-Pacific Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.1.  China Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.2.  Japan Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.3.  Korea Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.4.  India Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.5.  Southeast Asia Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.3.6.  Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.4.  South America Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.4.1.  Brazil Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.4.2.  Argentina Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.4.3.  Columbia Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.4.4.  Rest of South America Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.  Middle East and Africa Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.1.  Saudi Arabia Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.2.  United Arab Emirates Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.3.  Egypt Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.4.  Nigeria Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.5.  South Africa Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.6.  Turkey Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.2.5.7.  Rest of Middle East and Africa Central Nervous System (CNS) Therapeutic Market Forecast (2017-2027)

9.3.     Central Nervous System (CNS) Therapeutic Market Forecast by Disease (2017-2027)

9.3.1.  Central Nervous System (CNS) Therapeutic Forecast by Disease (2017-2027)

9.3.2.  Central Nervous System (CNS) Therapeutic Market Share Forecast by Disease (2017-2027)


List of Tables

List of Tables and Figures

Figure United States Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Central Nervous System (CNS) Therapeutic Revenue and Revenue Share by Disease (2017-2018)
Figure Global Trauma Revenue and Growth Rate (2017-2018)
Figure Global Degenerative Revenue and Growth Rate (2017-2018)
Figure Global Cancer Revenue and Growth Rate (2017-2018)
Figure Global Neurovascular Disease Revenue and Growth Rate (2017-2018)
Figure Global Mental Health Revenue and Growth Rate (2017-2018)
Figure Global Infections Revenue and Growth Rate (2017-2018)
Table Global Central Nervous System (CNS) Therapeutic Revenue by Regions (2017-2018)
Figure North America Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure North America Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2018)
Figure North America Central Nervous System (CNS) Therapeutic by Countries (2017-2018)
Figure North America Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2018)
Figure United States Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure United States Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Canada Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Mexico Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Europe Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2018)
Figure Europe Central Nervous System (CNS) Therapeutic by Countries (2017-2018)
Figure Europe Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2018)
Figure Germany Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Germany Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure France Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure UK Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Russia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Italy Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Rest of Europe Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Central Nervous System (CNS) Therapeutic by Countries (2017-2018)
Figure Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2018)
Figure China Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure China Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Japan Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Korea Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure India Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Southeast Asia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure South America Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2018)
Figure South America Central Nervous System (CNS) Therapeutic by Countries (2017-2018)
Figure South America Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Brazil Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Argentina Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Columbia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Rest of South America Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Central Nervous System (CNS) Therapeutic by Countries (2017-2018)
Figure Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Saudi Arabia Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure United Arab Emirates Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Egypt Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Nigeria Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure South Africa Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Turkey Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Central Nervous System (CNS) Therapeutic Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2017-2018)
Table Pfizer, Inc. Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Otsuka Pharmaceutical Co., Ltd. Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck & Co. Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Shire PLC Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharmaceuticals Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biogen, Inc. Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Eli Lily Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Astra Zeneca Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Johnson & Johnson Central Nervous System (CNS) Therapeutic Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Central Nervous System (CNS) Therapeutic Market Share by Manufacturer
Figure Global Central Nervous System (CNS) Therapeutic Revenue and Market Share by Manufacturer
Table Global Central Nervous System (CNS) Therapeutic Price by Region (2017-2017)
Figure Top 5 Central Nervous System (CNS) Therapeutic Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Central Nervous System (CNS) Therapeutic Revenue (Millions USD) and Growth Rate (2018-2025)
Table Central Nervous System (CNS) Therapeutic Market Forecast by Regions (2018-2025)
Figure North America Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure United States Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Canada Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Mexico Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Europe Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Germany Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure France Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure UK Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Russia Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Italy Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Rest of Europe Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Asia-Pacific Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure China Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Japan Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Korea Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure India Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Southeast Asia Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure South America Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Brazil Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Argentina Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Columbia Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Rest of South America Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Middle East and Africa Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Saudi Arabia Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure United Arab Emirates Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Egypt Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Nigeria Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure South Africa Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Turkey Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Central Nervous System (CNS) Therapeutic Market Forecast (2018-2025)
Figure Global Central Nervous System (CNS) Therapeutic Forecast by Disease (2018-2025)
Figure Global Central Nervous System (CNS) Therapeutic Market Share Forecast by Disease (2018-2025)
Figure Global Central Nervous System (CNS) Therapeutic Forecast by Disease (2018-2025)
Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country